News | June 24, 2024
Ascentage Pharma closes US$ 75 million equity investment by Takeda
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Subscribe To Our Newsletter & Stay Updated
